• Sharlow, E.R., Koseoglu, M.M., Bloom, G.S.,and Lazo, J.S. The promise and perils of compound discovery screening with inducible pluripotent cell-derived neurons. Assay Drug Dev Technol. 18:97-103, 2020.
  • Porterfield, V., Khan, S., Foff, E., Koseoglu, M.M., Blanco, I.K., Jayaraman, S. Lien, E., McConnell, M.J., Bloom, G.S., Lazo, J.S., and Sharlow, E.R. A three-dimensional dementia model reveals spontaneous cell cycle reentry and a senescence-associated secretory phenotype. Neurobiol Aging. 90:125-134, 2020.
  • Aguilar-Sopeña, O., Hernández-Pérez, S., Alegre-Gómez, S., Castro-Sánchez, P., Iglesias-Ceacero, A., Lazo, J.S., and Roda-Navarro, P. Effect of pharmacological inhibition of the catalytic activity of phosphatases of regenerating liver in early T cell receptor signaling dynamics and IL-2 production. Int J Mol Sci. 5:21, 2020.


  • Tasker, N.R., Rastelli, E.J., Blanco, I.K., Burnett, J.C., Sharlow, E.R.,Lazo, J.S., and Wipf, P.  In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors.  Org Biomol Chem. 17:2448-2466, 2019.
  • Koseoglu, M.M., Norambuena, A., Sharlow, E.R.,Lazo, J.S., and Bloom, G.S. Aberrant neuronal cell cycle re-entry: The pathological confluence of Alzheimer’s Disease and brain insulin resistance, and Its relation to cancer. J Alzheimer’s Dis. 67:1-11, 2019.
  • Lazo, J.S., Blanco, I.K., Tasker, N.R., Rastelli, E.J., Burnett, J.C., Garrott, S.R., Hart, D.J., McCloud, R.L., Hsu, K.-L., Wipf, P. and Sharlow, E.R. Next-generation cell-active inhibitors of the undrugged oncogenic PTP4A3 phosphatase. J Pharmacol Exptl Therap. 371:652-662, 2019.
  • Sharlow, E.R., Koseoglu, M.M., Bloom, G.S.,and Lazo, J.S. The promise and perils of compound discovery screening with inducible pluripotent cell-derived neurons. Assay Drug Dev Technol. In Press. doi: 10.1089/adt.2019.914.
  • Lazo, J.S. and Lau, A.F. What snaps your socks – A tribute to Dr. Raymond (Ray) W. Ruddon. The Pharmacologist. 61:184, 2019.
  • Lazo, J.S. The hubris and humility of cancer pharmacology in the post-immuno-oncology era. Pharmacol Res Perspec. 7:e00527, 2019


  • McQueeney, K.E., Salamoun, J.E., Anh, J., Pekic, P., Blanco, I.K., Struckman, H., Sharlow, E.R., Wipf, P., and Lazo, J.S. PTP4A3 phosphatase regulates colorectal cancer cell migration, adhesion and Emilin 1 gene expression. FASEB J. 32: 5661-5673, 2018.
  • Johnston, P.A., Sen, M., Hua, Y., Camarco, D.P., Shun, T.Y., Lazo, J.S., and Grandis, J.R. High content imaging assays for IL-6-induced STAT3 pathway activation in Head and Neck cancer cell lines. Methods Mol Biol.1683:229-244, 2018.
  • Lazo, J.S. Refining radiation in the next century. Mol Cancer Therap. 17:332-335, 2018.
  • Lazo, J.S. Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches. F1000Res. 7:308, 2018


  • McQueeney, K.E., Salamoun, J.M., Burnett, J.C., Barabutis, N., Pekic, P., Lewandowski, S.L., Llaneza, D.C., Cornelison, R., Bai, Y., Zhang, Z.-Y., Catravas, J.D., Landen Jr., C.N., Wipf, P., Lazo, J.S., and Sharlow, E.R. Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor. Oncotarget. 9:8223-8240.
  • Lazo, J.S., McQueeney, K.E. and Sharlow, E.R. New approaches to difficult drug targets: The phosphatase story. SLAS Discovery, 2472555217721142, 2017.
  • Bloom, G., Lazo, J.S. and Norambuena, A. Reduced brain insulin signaling: a seminal process in Alzheimer’s disease pathogenesis. Neuropharmacology. S0028-3908:30433-1, 2017.
  • Lazo, J.S., McQueeney, K.E., Birnett, J.C., Wipf, P., and Sharlow, E.R. Small targeting of PTPs in cancer. Int J Biochem Cell Biol S1357-2725:30237-6, 2017


  • Sharlow, E.R., Leimgruber, S., Lira, A., McConnell, M.J., Norambuena, A., Bloom, G.S., Epperly, M.W., Greenberger, J.S., and Lazo, J.S. A small molecule screen exposes mTOR signaling pathway involvement in radiation-induced apoptosis. ACS Chem Biol. 11:1428-1437, 2016.
  • Johnston, P.A., Nguyen, M.M., Dar, J.A., Ai, J., Wang, Y., Masoodi, K.Z., Shun, T., Shinde, S., Camarco, D.P., Hua, Y., Huryn, D.M., Wilson, G.M., Lazo, J.S., Nelson, J.B., Wipf, P., and Wang Z. Development and implementation of a high-throughput high-content screening assay to identify inhibitors of androgen receptor nuclear localization in castration-resistant prostate cancer cells. Assay Drug Dev Technol. 14:226-239, 2016.
  • Salamoun, J.M., McQueeney, K.E., Patil, K., Geib, S.J., Sharlow, E.R., Lazo, J.S., and Wipf, P. Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor. Org Biomol Chem. 14:6398-6402, 2016.
  • LaPorte, M.G., Wang, Z., Colombo, R., Garzan, A., Peshkov, V.A., Liang, M., Johnston, P.A., Schurdak, M.E., Sen, M., Camarco, D.P., Hua, Y., Pollock, N.I., Lazo, J.S., Grandis, J.R., Wipf, P., and Huryn, D.M. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorg Med Chem Lett. 26: 3581-3585. 2016.
  • Lazo, J.S. and Sharlow, E.R. Drugging Undruggable Molecular Cancer Targets. Annu Rev Pharmacol Toxicol. 56: 23-40, 2016


  • George Rosenker, K.M., Paquette, W.D., Johnston, P.A., Sharlow, E.R., Vogt, A., Bakan, A., Lazo, J.S., and Wipf, P. Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B. Bioorg Med Chem. 23:2810-2818, 2015.
  • Johnston, P.A., Sen, M., Hua, Y., Camarco, D.P., Shun, T.Y., Lazo, J.S., Wilson, G.M., Resnick, L.O., LaPorte, M.G., Wipf, P., Huryn, D.M., and Grandis, J.R. HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol. 13:356-376, 2015.
  • Wang, H., Teriete, P., Hu, A., Raveendra-Panickar, D., Pendelton, K., Lazo, J.S., Eiseman, J., Holien, T., Misund, K., Oliynyk, G., Arsenian-Henriksson, M., Cosford, N.D., Sundan, A., and Prochownik, E.V. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. Oncotarget. 6:32380-32395, 2015.




  • Zellefrow, C.D., Sharlow, E.R., Epperly, M.W., Reese, C.E., Shun, T., Lira, A., Greenberger, J.S., and Lazo, J.S.. Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay. Radiation Res. 178:150-150, 2012.
  •  McInnes, C., Estes, K., Baxter, M., Yang, Z., Farag, D. B., Johnston, P., Lazo, J.S., Wng. J. and Wyatt, M.D. Targeting subcellular localization through the Polo-Box domain: Non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Therap. 11:1683-1692, 2012.
  • Johnston, P.A., Shinde, S.N., Hua, Y, Shun, T. Y., Lazo, J.S., and Day, B.W. Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus. Assay Drug Dev Technol. 10:432-456, 2012.
  • Svilar, D., Dyavaiah, M., Brown, A.R., Tang, J., McDonald, P.R., Shun, T. Y., Wang, X-H., Lazo, J.S., Pollack, I.F., Begley, T.J. and Sobol, R. W. Alkylation sensitivity screens reveal a conserved cross-species functionome. Mol Cancer Res., 11:1683-1692, 2012.
  • Zhang, F., Rothermund, K, Gangadharan, S.B., Pommier, Y., Prochownik, E.V., and Lazo, J.S. Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target. Oncotarget. 3:998-1010, 2012.
  • Greenberger, J.S., Clump, D., Kagan, V., Bayir, H., Lazo, J.S., Wipf, P. Li, S., Gao, X., and Epperly, M.W. Strategies for discovery of small molecule radiation protectors and radiation mitigators. Frontiers in Oncology. 1:1-12, 2012.


  •  Vollmer, L.L., Jiménez, M., Camarco, D.P., Zhu, W., Daghestani, H.N., Balachandran, R., Reese, C.E., Lazo, J.S., Hukriede, N.A., Curran, D.P., Day, B.W., and Vogt, A. A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos. Mol Cancer Ther 10:994-1006, 2011.
  • Bravo-Altamirano, K., George, K.M., Frantz, M.C., Lavalle, C.R., Tandon, M., Leimgruber, S., Sharlow, E.R., Lazo, J.S., Wang, Q.J., and Wipf, P. Synthesis and structure-activity relationships of benzothienothiazepinone inhibitors of Protein Kinase D. ACS Med Chem Lett. 2:154-159, 2011.
  • Wang, Y., and Lazo, J.S. Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion. 31:818-827, 2011.
  • Kitchens ,C.A., McDonald, P.R., Shun, T.Y., Pollack, I.F., and Lazo, J.S. Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens. J Pharmacol Exp Ther. 339:851-858, 2011.
  • Ma, C., Lazo, J.S., and Xie, X.Q. Compound acquisition and prioritization algorithm for constructing structurally diverse compound libraries. ACS Comb Sci. 13:223-231, 2011.
  • George, K.M., Frantz, M.C., Bravo-Altamirano, K., Lavalle, C.R., Tandon, M., Leimgruber, S., Sharlow, E.R., Lazo, J.S., Wang, Q.J., and Wipf, P. Design, synthesis, and biological evaluation of PKD inhibitors. 3:186-228, 2011.
  • Zhang, Y., Xie, Z., Wang, L., Schreiter, B., Lazo, J.S., and Gertsch J, and Xie, X.Q. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. Int Immunopharmacol. 11:1303-1310, 2011.
  • Sharlow, E.R., Mustata Wilson, G., Close, D., Leimgruber, S., Tandon, M., Reed, R.B., Shun, T.Y., Wang, Q.J., Wipf, P., and Lazo, J.S. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity. PLoS One 6:e25134, 2011.
  • Lazo, J.S. Molecular Interventions (2001-2011): an experiment completed. Mol Interv 11:62, 2011.